title: FAS/FASL expression profile as a prognostic marker in squamous cell carcinoma of the oral cavity.
abstract: FAS/FASL altered expression may cause tumor protecting immunomodulation, with a direct impact on patient prognosis. FAS expression was studied in 60 squamous cell carcinomas of the oral cavity. FAS expression did not show a significant association with tumor histopathological characteristics, but was significantly associated with lymph node positivity. FAS expression was significantly associated with disease specific death and negative FAS expression was an independent risk factor, increasing risk 4 times when compared to positive expression. When FAS and FASL expression results were combined, we were able to define high, intermediate and low risk profiles. Disease-free and disease-specific survival were significantly correlated with FAS/FASL expression profiles. The high risk category was an independent marker for earlier disease relapse and disease-specific death, with approximately 4- and 6-fold increased risk, respectively, when compared to the low risk profile. Risk profiles based on FAS/FASL expression showed that high risk was significantly associated with increased disease relapse and death, as well as shorter disease-free or disease-specific survival. This categorization, added to patient clinical data, may facilitate the choice of therapy, minimizing treatment failure and increasing disease control.
authors.affiliation: Serviço de Cirurgia de Cabeça e Pescoço, Hospital Heliópolis, São Paulo, São Paulo, Brazil.
authors.forename: Paulo Bentes
authors.initials: PB
authors.lastname: de Carvalho-Neto
authors.forename: Marcelo
authors.initials: M
authors.lastname: dos Santos
authors.forename: Marcos Brasilino
authors.initials: MB
authors.lastname: de Carvalho
authors.forename: Ana Maria da Cunha
authors.initials: AM
authors.lastname: Mercante
authors.forename: Viviane Priscila Pina
authors.initials: VP
authors.lastname: dos Santos
authors.forename: Patrícia
authors.initials: P
authors.lastname: Severino
authors.forename: Eloiza Helena
authors.initials: EH
authors.lastname: Tajara
authors.forename: Iuri Drumond
authors.initials: ID
authors.lastname: Louro
authors.forename: Adriana Madeira Álvares
authors.initials: AM
authors.lastname: da Silva-Conforti
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D053222:Fas Ligand Protein / Q000235:genetics / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D012008:Recurrence; D047368:Tumor Burden; D019014:fas Receptor / Q000235:genetics / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D053222:Fas Ligand Protein; D019014:fas Receptor
references.citation: Head Neck. 2005 Dec;27(12):1080-91
references.pmid: 16240329
references.citation: Hepatology. 1999 Aug;30(2):413-21
references.pmid: 10421649
references.citation: Neoplasia. 2011 Mar;13(3):198-205
references.pmid: 21390183
references.citation: Cancer Res. 1997 Mar 15;57(6):1007-12
references.pmid: 9067260
references.citation: Clin Cancer Res. 2012 Nov 15;18(22):6147-54
references.pmid: 23014525
references.citation: Head Neck. 2004 Aug;26(8):660-74
references.pmid: 15287033
references.citation: Otolaryngol Clin North Am. 1998 Aug;31(4):671-86
references.pmid: 9687328
references.citation: J Exp Med. 1998 Nov 2;188(9):1717-23
references.pmid: 9802983
references.citation: Semin Cancer Biol. 2003 Apr;13(2):97-105
references.pmid: 12654253
references.citation: Curr Opin Cell Biol. 1999 Apr;11(2):255-60
references.pmid: 10209153
references.citation: Ann N Y Acad Sci. 1998 Apr 15;842:82-90
references.pmid: 9599297
references.citation: J Assist Reprod Genet. 1999 Nov;16(10):512-9
references.pmid: 10575578
references.citation: Ann Surg Oncol. 2000 Dec;7(10):750-7
references.pmid: 11129423
references.citation: Cell Death Differ. 2003 Jan;10(1):117-23
references.pmid: 12655300
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2003 Apr;27(2):199-214
references.pmid: 12657360
references.citation: Folia Histochem Cytobiol. 2010 Sep 30;48(3):425-9
references.pmid: 21071349
references.citation: Exp Mol Pathol. 2001 Jun;70(3):255-64
references.pmid: 11418004
references.citation: Oncogene. 1999 Jun 24;18(25):3754-60
references.pmid: 10391683
references.citation: Br J Cancer. 2000 Oct;83(7):880-6
references.pmid: 10970689
references.citation: Mol Cell Biochem. 2009 Jan;321(1-2):95-102
references.pmid: 18830569
references.citation: Curr Opin Oncol. 2012 May;24(3):235-42
references.pmid: 22327839
references.citation: Anticancer Res. 2007 Nov-Dec;27(6B):4083-6
references.pmid: 18225575
references.citation: BMC Res Notes. 2008 Nov 13;1:113
references.pmid: 19014556
references.citation: J Clin Invest. 1998 Mar 1;101(5):1102-10
references.pmid: 9486981
references.citation: J Med Genet. 2005 Jun;42(6):479-84
references.pmid: 15937082
references.citation: World J Gastroenterol. 2010 Mar 14;16(10):1274-8
references.pmid: 20222173
references.citation: Clin Cancer Res. 2000 Dec;6(12):4755-9
references.pmid: 11156230
references.citation: Mod Pathol. 2002 Dec;15(12):1374-80
references.pmid: 12481020
references.citation: Carcinogenesis. 2005 Feb;26(2):263-70
references.pmid: 15375012
references.citation: Crit Rev Oncol Hematol. 2003 Jan;45(1):37-53
references.pmid: 12482571
references.citation: J Natl Cancer Inst. 2004 Jul 7;96(13):1030-6
references.pmid: 15240787
references.citation: Int J Hematol. 2001 Jun;73(4):438-452
references.pmid: 11503957
references.citation: Stem Cells Dev. 2004 Oct;13(5):473-83
references.pmid: 15588505
references.citation: Head Neck. 2011 Jun;33(6):817-23
references.pmid: 20737489
references.citation: Alcohol Alcohol. 1999 Nov-Dec;34(6):830-41
references.pmid: 10659718
references.citation: Folia Histochem Cytobiol. 2011;49(2):231-9
references.pmid: 21744322
references.citation: BMJ. 2001 Jun 23;322(7301):1538-9
references.pmid: 11420280
references.citation: Front Biosci. 1997 Jul 15;2:d353-79
references.pmid: 9230063
references.citation: Br J Cancer. 2000 May;82(10):1747-54
references.pmid: 10817513
references.citation: Cancer Res. 1999 Oct 15;59(20):5356-64
references.pmid: 10537320
references.citation: Inflamm Res. 2011 May;60(5):409-24
references.pmid: 21298317
references.citation: Int J Cancer. 1994 May 1;57(3):371-7
references.pmid: 8168998
references.citation: Cancer Res. 1998 May 15;58(10):2057-62
references.pmid: 9605741
references.citation: Ann Hematol. 2005 Oct;84(10):627-39
references.pmid: 16041532
references.citation: Hum Pathol. 2002 Oct;33(10):968-74
references.pmid: 12395368
references.citation: J Cell Biochem. 1995 Jun;58(2):175-80
references.pmid: 7673325
references.citation: J Leukoc Biol. 2008 Mar;83(3):774-84
references.pmid: 18055568
references.citation: Endocr J. 2001 Jun;48(3):289-301
references.pmid: 11523899